Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 12:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 2 Interventional Results available

Safety and Efficacy of Secukinumab in Mild Psoriasis

NCT03131570
Conditions
Psoriasis
Interventions
Secukinumab, Placebo followed by Secukinumab
Drug
Lead sponsor
James G. Krueger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Moderate to Severe Plaque-type Psoriasis
Interventions
AIN457 150mg, AIN457 300mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
967 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Fresno, California • Pasadena, California • Sacramento, California + 28 more
Conditions
Psoriasis
Interventions
Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg, Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg
Drug
Lead sponsor
Centocor Research & Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 25 more
Conditions
Psoriasis
Interventions
Ixekizumab, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
31
States / cities
Bakersfield, California • New Haven, Connecticut • Washington D.C., District of Columbia + 28 more
Conditions
Psoriasis, Skin Diseases
Interventions
Orismilast modified release tablets, Placebo
Drug
Lead sponsor
UNION therapeutics
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Cromwell, Connecticut • Washington D.C., District of Columbia • Beverly, Massachusetts + 3 more
Conditions
Psoriasis
Interventions
Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Psoriasis
Interventions
CEP-701 20mg, CEP-701 40mg, CEP-701 60mg, CEP-701 80mg
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Winston-Salem, North Carolina • Dallas, Texas • Norfolk, Virginia
Completed Phase 2 Interventional Results available

Rimegepant in Moderate Plaque-type Psoriasis

NCT04629950
Conditions
Psoriasis
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
New York, New York
Conditions
Plaque-type Psoriasis
Interventions
COL-121, 50 µg/g Calcipotriene Ointment, Placebo
Drug
Lead sponsor
Deltanoid Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Fremont, California • Los Angeles, California • San Diego, California + 17 more
Conditions
Psoriasis
Interventions
JNJ-38518168 60 mg, JNJ-38518168 30 mg, JNJ-38518168 3 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Los Angeles, California • Santa Monica, California • Atlanta, Georgia + 7 more
Conditions
Moderate to Severe Chronic Plaque-type Psoriasis
Interventions
secukinumab low dose, secukinumab high dose
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Fountain Valley, California • Jacksonville, Florida • Lebanon, New Hampshire + 1 more
Conditions
Psoriasis
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Ocala, Florida • Rolling Meadows, Illinois • Plainfield, Indiana + 5 more
Conditions
Psoriasis
Interventions
CP-690,550, Placebo/CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
44
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Bakersfield, California + 33 more
Conditions
Moderate to Severe Plaque-type Psoriasis
Interventions
Secukinumab (AIN457), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 28 more
Conditions
Psoriasis
Interventions
Acitretin 17.5 mg/day
Drug
Lead sponsor
Frankel, Amylynne, M.D.
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
New York, New York
Conditions
Plaque Type Psoriasis
Interventions
GP2017 Adalimumab, Humira ® Adalimumab
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
69
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 60 more
Conditions
Psoriasis
Interventions
ustekinumab, placebo
Drug
Lead sponsor
Centocor Research & Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
766 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Phoenix, Arizona • Los Angeles, California • Redwood City, California + 25 more
Conditions
Plaque Psoriasis
Interventions
Enstilar
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Completed Phase 2 Interventional Results available

Tofacitinib Ointment For Chronic Plaque Psoriasis

NCT01831466
Conditions
Psoriasis Vulgaris, Psoriasis
Interventions
tofacitinib ointment 20 mg/g, tofacitinib ointment 10 mg/g, placebo ointment (vehicle)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
29
States / cities
Hot Springs, Arkansas • Bakersfield, California • Irvine, California + 22 more
Conditions
Psoriasis
Interventions
Calcipotriene Foam, Vehicle Foam
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
26
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 22 more
Conditions
Moderate to Severe Plaque-type Psoriasis
Interventions
secukinumab 150 mg, placebo to secukinumab 150 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
Conditions
Psoriasis
Interventions
AN2728 ointment, 2%, Ointment Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
10
States / cities
New Haven, Connecticut • Louisville, Kentucky • Fridley, Minnesota + 7 more
Conditions
Plaque Psoriasis, Psoriasis Vulgaris
Interventions
Taclonex Ointment and Hydrogel Patch, Taclonex Ointment
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Francisco, California
Conditions
Psoriasis
Interventions
risankizumab
Biological
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
2,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
79
States / cities
Birmingham, Alabama • Rogers, Arkansas • Bakersfield, California + 65 more